Last reviewed · How we verify
NCT04844242: COVID-19
MISC COVID-19 Study in Pediatric Population
trial in SARS-CoV2 Infection in 180 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Tuberculosis Research Centre, India |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 23 December 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across India |
Conditions studied
- SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →
- Multisystem Inflammatory Syndrome in Children — all drugs for Multisystem Inflammatory Syndrome in Children →
Sponsor
Tuberculosis Research Centre, India — full company profile →
Who can join
Adults 1 to 15, any sex, with SARS-CoV2 Infection or Multisystem Inflammatory Syndrome in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rationale: Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV2) and its related Coronavirus Disease - 19 (COVID-19) has become a health emergency worldwide. The medical community has been concerned since the beginning of the outbreak about the potential impact of COVID-19 in children, especially in those with underlying chronic diseases. Fortunately, COVID-19 has been reported to be less severe in children than in adults. Unfortunately, a new multisystem inflammatory syndrome apparently related to infection with SARS-CoV-2 has recently been reported in older children (known as MIS-C), manifested by severe abdominal pain, cardiac dysfunction and shock. However, the SARS-CoV2 infection and the underlying immunology of COVID-19, its correlation with disease severity and MIS-C in children is not fully explored. Objectives: To perform systems immunology and strain diversity among SARS-CoV2 and MIS-C infected children. Study design: Cross sectional study. Study population: Children attending outpatients units and admitted in wards in pediatric hospitals in Chennai. Main study parameters/endpoints: Immune responses in children with SARS-CoV2 infection and multisystem inflammatory syndrome in children (MIS-C) infection and its association of SARS-CoV2 viral diversity.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Sex-specific differences in systemic immune responses in MIS-C children.
Rajamanickam A, Kumar NP, Venkataraman A, Varadarjan P, et al · · 2024 · cited 11× · PMID 38243064 · DOI 10.1038/s41598-024-52116-1 -
Role of matrix metalloproteinases in multi-system inflammatory syndrome and acute COVID-19 in children.
Pavan Kumar N, Venkataraman A, Varadarjan P, Nancy A, et al · · 2022 · cited 8× · PMID 36544496 · DOI 10.3389/fmed.2022.1050804 -
Unique cellular immune signatures of multisystem inflammatory syndrome in children.
Rajamanickam A, Nathella PK, Venkataraman A, Varadarjan P, et al · · 2022 · cited 6× · PMID 36322537 · DOI 10.1371/journal.ppat.1010915
Verify or expand the search:
- PubMed search for NCT04844242
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV2 Infection
Currently open trials in the same condition.
- NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
Other Tuberculosis Research Centre, India trials
Trials by the same sponsor.
- NCT05047055 — Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients · unknown
- NCT05040126 — Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India · Phase 3 · unknown
- NCT04930978 — Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis · unknown
- NCT05049187 — Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers · completed
- NCT05044910 — The Impact of Malnutrition on Immune Responses to Tuberculosis · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04844242 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tuberculosis Research Centre, India
- Last refreshed: 30 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04844242.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing